Abhijeet Patra

Topo1-based ADCs are broadly seen as superior to MMAE-based ADCs but apparently not for every target or indication. 2 papers out last week showing comparable efficacy in gastric cancer for two different topo1 CLDN18.2 ADCs in "biomarker positive" patients but efficacy is relatively modest at the go forward doses. ___LINE... See more

Church lab automates 12 years of research in 2 days Sometimes I have the privilege of receiving emails from people telling me about their breakthroughs. In such cases, it gives me great pleasure to help advance scientific knowledge by giving it a little reach with my modest means. And what these young scientists have di... See more

This brings up a really interesting tension around how much self-optimization through constant data collection is empowering vs. extractive Data is the most important currency of our times, and your 24/7 data stream is very valuable I explore this here: https://t.co/FoEdPri4p3... See more

Had a conversation with someone outside of healthcare recently who was shocked by how long it takes to run clinical trials in the U.S (not to mention expensive). I tried to explain—it’s not just the science. It’s the infrastructure. Every site needs dozens of personnel, many of whom are required by regulatory frameworks... See more